Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Revenue: ¥1,733 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600222 Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
62 GF Score
Price ¥8.61
GF Value ¥4.96
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Henan Taloph Pharmaceutical Stock Co Revenue?

Henan Taloph Pharmaceutical Stock Co SHSE:600222 +0.12% 62 Revenue is ¥1,733 Mil as of Jun. 2026. GuruFocus rates SHSE:600222 with a GF Score™ of 62/100 and a GF Value™ of ¥4.96 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Henan Taloph Pharmaceutical Stock Co's revenue for the three months ended in Jun. 2026 was ¥388 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ¥1,733 Mil. Henan Taloph Pharmaceutical Stock Co's Revenue per Share for the three months ended in Jun. 2026 was ¥0.71. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ¥3.14.

Warning Sign:

Henan Taloph Pharmaceutical Stock Co Ltd revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Henan Taloph Pharmaceutical Stock Co was -2.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -3.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 4.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Henan Taloph Pharmaceutical Stock Co's highest 3-Year average Revenue per Share Growth Rate was 47.10% per year. The lowest was -17.10% per year. And the median was 9.90% per year.


Henan Taloph Pharmaceutical Stock Co  (SHSE:600222) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Henan Taloph Pharmaceutical Stock Co Revenue Related Terms


Henan Taloph Pharmaceutical Stock Co Revenue Historical Data

* Premium members only.

The historical data trend for Henan Taloph Pharmaceutical Stock Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Henan Taloph Pharmaceutical Stock Co Revenue Chart

Henan Taloph Pharmaceutical Stock Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,604.52 1,960.69 2,069.91 1,941.42 1,757.79

Henan Taloph Pharmaceutical Stock Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 439.16 424.47 570.89 350.23 387.82

SHSE:600222 vs ZTS: Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Henan Taloph Pharmaceutical Stock Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Henan Taloph Pharmaceutical Stock Co Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Henan Taloph Pharmaceutical Stock Co's Revenue distribution charts can be found below:

* The bar in red indicates where Henan Taloph Pharmaceutical Stock Co's Revenue falls into.


SHSE:600222
62GF Score
Henan Taloph Pharmaceutical Stock Co Ltd SHSE:600222
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Henan Taloph Pharmaceutical Stock Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,733 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of ¥1,733 Mil mean?
Henan Taloph Pharmaceutical Stock Co (SHSE:600222) has a Revenue of ¥1,733 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors.
Is Henan Taloph Pharmaceutical Stock Co's Revenue too high?
Henan Taloph Pharmaceutical Stock Co's current Revenue is ¥1,733 Mil. Overall, Henan Taloph Pharmaceutical Stock Co has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Henan Taloph Pharmaceutical Stock Co's Revenue compare to ZTS?
Henan Taloph Pharmaceutical Stock Co's Revenue of ¥1,733 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Henan Taloph Pharmaceutical Stock Co and its competitors. Henan Taloph Pharmaceutical Stock Co's current Revenue is ¥1,733 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Henan Taloph Pharmaceutical Stock Co stock overvalued right now?
Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co (SHSE:600222) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥4.96, compared to a current price of ¥8.61 — trading 73.6% above its estimated fair value. The current Revenue is ¥1,733 Mil. Henan Taloph Pharmaceutical Stock Co's overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Henan Taloph Pharmaceutical Stock Co (SHSE:600222), the current Revenue is ¥1,733 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Henan Taloph Pharmaceutical Stock Co (SHSE:600222) Overvalued in 2026?

Based on GuruFocus' analysis, Henan Taloph Pharmaceutical Stock Co stock appears to be overvalued. The current stock price of ¥8.61 is trading 73.6% above its estimated GF Value™ of ¥4.96. GuruFocus considers Henan Taloph Pharmaceutical Stock Co to be Significantly Overvalued.

Key valuation signals for SHSE:600222:

  • Revenue: ¥1,733 Mil
  • GF Value™: ¥4.96 vs. price of ¥8.61 (73.6% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the SHSE:600222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Henan Taloph Pharmaceutical Stock Co Business Description

Address No. 8, Jinsuo Road, High-tech Industrial Development Zone, Henan Province, Zhengzhou, CHN, 450001
Henan Taloph Pharmaceutical Stock Co Ltd is a Chinese company engaged in pharmaceutical manufacturing and pharmaceutical research and development services, including pharmaceutical preparations, Chinese herbal medicine slices, and pharmaceutical research and development services. The company's pharmaceutical preparation business is mainly based on oral Chinese medicine preparations, and its treatment areas cover the respiratory system, cardiovascular and cerebrovascular system, digestive system, and nervous system.
62GF Score

Get the complete analysis for SHSE:600222

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.61
Price
¥4.96
GF Value